ERBB2 and breast carcinoma: Using univariate analysis, an elevated risk of breast-cancer-specific death was identified in the TNBC subtype, with an OR of 1.40 (95% CI: 1.32–1.50, p < 0.001), and a decreased risk was observed in the HER2+/HR+ subtype (OR: 0.69; 95% CI: 0.64–0.75, p < 0.001).